| Title |
COVIDOSE: A Phase II Clinical Trial of Low‐Dose Tocilizumab in the Treatment of Noncritical COVID‐19 Pneumonia
|
|---|---|
| Published in |
Clinical Pharmacology & Therapeutics, December 2020
|
| DOI | 10.1002/cpt.2117 |
| Pubmed ID | |
| Authors |
Garth W. Strohbehn, Brian L. Heiss, Sherin J. Rouhani, Jonathan A. Trujillo, Jovian Yu, Alec J. Kacew, Emily F. Higgs, Jeffrey C. Bloodworth, Alexandra Cabanov, Rachel C. Wright, Adriana K. Koziol, Alexandra Weiss, Keith Danahey, Theodore G. Karrison, Cuoghi C. Edens, Iazsmin Bauer Ventura, Natasha N. Pettit, Bhakti K. Patel, Jennifer Pisano, Mary E. Strek, Thomas F. Gajewski, Mark J. Ratain, Pankti D. Reid |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 71% |
| France | 1 | 14% |
| Unknown | 1 | 14% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 71% |
| Scientists | 2 | 29% |
Mendeley readers
The data shown below were compiled from readership statistics for 155 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 155 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 18 | 12% |
| Other | 16 | 10% |
| Researcher | 12 | 8% |
| Student > Master | 11 | 7% |
| Student > Doctoral Student | 8 | 5% |
| Other | 22 | 14% |
| Unknown | 68 | 44% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 46 | 30% |
| Nursing and Health Professions | 10 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 3% |
| Agricultural and Biological Sciences | 4 | 3% |
| Other | 10 | 6% |
| Unknown | 72 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 April 2021.
All research outputs
#3,034,635
of 25,218,929 outputs
Outputs from Clinical Pharmacology & Therapeutics
#568
of 4,489 outputs
Outputs of similar age
#79,084
of 523,131 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#12
of 61 outputs
Altmetric has tracked 25,218,929 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,489 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 523,131 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.